This invention involves our development of novel Galectin-Immunoglobulin Ig Fc fusion constructs (Gal-Fc). These fusion proteins behave as stable, high-affinity receptors which bind native galectin ligands on intact melanoma/cancer and immune cells and in cell lysates. Gal-Fc molecules are versatile tools for immuno-detection assays, including Western blotting, flow cytometry, and immunohistochemistry. These new glycobiological probes are fully functional, active, potent and have therapeutic applications for biomedical research, clinical utility and biomarker development. For additional information please see the links below and our Publications.

Patent Title: Galectin-Immunoglobulin Chimeric Molecules.
Inventors: Drs. Charles J. Dimitroff, Filiberto Cedeno Laurent, Steven R. Barthel
Assignee: Brigham and Women’s Hospital, Harvard Medical School
Patent Filed: 12/02/2013
Patent Issued: 06/19/2014
US Patent Number: 20140171621

Patent links:


HARVARD STEM CELL INSTITUTE                                       CFG